Clade specific neutralising vaccines for HIV: An appropriate target?

Current HIV Research

Volumn 5, Issue 6, 2007, Pages 554-560

  McKnight, Áine ^a   Aasa Chapman, Marlén M I ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibodies; Clades; HIV; Neutralisation; Subtypes; Vaccines

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG TARGETING; ENZYME BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; NONHUMAN; PROTEIN TARGETING; REVIEW; VIRUS CELL INTERACTION;

AIDS VACCINES; ANTIBODY SPECIFICITY; ANTIGENS, CD4; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS;

EID: 38949183739     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207782418524     Document Type: Review

References (92)

1. Aasa-Chapman MM, Aubin K, Williams I, McKnight A. (2006). Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology. 351: 489-496.
2. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A. (2004). Development of the antibody response in acute HIV-1 infection. AIDS. 18: 371-381.
3. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P, McKnight A. (2005). Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. Journal of Virology. 79: 2823-2830.
4. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Berracky, PJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM. (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency-virus infection. Nature Medicine. 6: 200-206.
5. Barin F, Brunet S, Brand D, Moog C, Peyre R, Damond F, Charneau. P, Barre-Sinoussi F. (2004). Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. Journal of Infectious Disesases. 189: 322-327.
6. Beirnaert E, Nyambi P, Willems B, Heyndrickx L. Colebunders R, Janssens W, van der Groen G. (2000). Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. Journal of Medical Virology. 62: 14-24.
7. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. (2004). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology. 78: 13232-13252.
8. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. (2007). HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS. 21: 693-702.
9. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA. (1994). Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology. 68: 6006-6013.
10. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, Montefiori DC. (2002). Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. Journal of Virology. 76: 2233-2244.
11. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. (2003). Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 300: 2065-2071.
12. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, Sodroski J. (1997). Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. Journal of Virology. 71: 9808-9812.
13. Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H. Robinson J, van der Groen G, Quinnan GV, Jr. (2006). Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology. 347: 36-51.
14. Charneau P, Borman AM, Quillent C, Guetard D, Chamaret S, Cohen J, Remy G, Montagnier L, Clavel F. (1994). Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology. 205: 247-253.
15. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. (2005). Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 433: 834-841.
16. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B Overbaugh J. (2005). Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. Journal of Virology. 79: 6528-6531.
17. Clapham PR, McKnight A. (2002). Cell surface receptors, virus entry and tropism of primate lentiviruses. Journal of General Virology. 83: 1809-1829.
18. Cormier EG, Dragic T.(2002) The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. Journal of Virology. 76: 8953-8957.
19. Dacheux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, Barin F. (2004). Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. Journal of Virology. 78: 12625-12637.
20. De Leys R, Vanderborght B, Vanden Haesevelde M, Heyndrickx L, van Geel A, Wauters C, Bernaerts R, Saman E, Nijs P, Willems B. (1990). Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin. Journal of Virology. 64: 1207-1216.
21. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM. (2005). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. Journal of Experimental Medicine. 201: 1407-1419.
22. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission: Science. 303: 2019-2022.
23. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR. (2007). Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. Journal of Virology. 81: 6548-6562.
24. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD. (2005). Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and-neutralizing antibody responses during transmission of HIV-1 subtype B. Journal of Virology. 79: 6523-6527.
25. Gaschen B, Kober B, Foley D. (1999). Global variation in the HIV-1 V3 region. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors JW, Mullins J, Wolinsky S, Korber B Eds, Human Retroviruses and AIDS. Los Alamos, Los Alamos National Laboratory. pp. 594-602.
26. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. (2002). Diversity considerations in HIV-1 vaccine selection. Science. 296: 2354-2360.
27. Gauduin MG, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. (1997). Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Medicine. 3: 1389-1393.
28. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. Journal of Virology. 66: 7538-7542.
29. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. (2006). Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Medicine. 3: e255.
30. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L. (2007). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Journal of Virology, 81: 6187-6196.
31. Hemelaar J, Gouws E, Ghys PD, Osmanov S. (2006). Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 20: W13-23.
32. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. (2005). Structure of a V3-containing HIV-1 gp120 core. Science. 310: 1025-1028.
33. Kelly HR, Urbanski M, Burda S, Zhong P, Konings F, Nanfack J, Tongo M, Kinge T, Achkar J, Nyambi P. (2005). Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals. Human Antibodies. 14: 89-99.
34. Kostrikis LG, Michalopoulou ZH, Cao Y, Moore JP, Ho DD. (1996). Determining neutralization scrotypes of HIV type 1 by neural networks. AIDS Research and Human Retroviruses. 12: 1667-1669.
35. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393: 648-659.
36. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR. (2003). Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. Journal of Virology. 77: 10557-10565.
37. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA. (2006). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of Virology. 80: 5211-5218.
38. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology. 79: 10108-10125.
39. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. (2006). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. Journal of Virology. 80: 11776-11790.
40. Louder MK, Sambor A, Chertova E, Hunte T, Barren S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR. (2005). HIV-1 envelope pseudotyped vital vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology. 339: 226-238.
41. Louisirirotchanakul S, Beddows S, Cheingsong-Popov, R, Shaffer N, Mastro TD, Auewarakul P, Likanonsakul S, Wasi C, Weber J. (1998). Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 19: 315-320.
42. Malenbaum SE, Yang D, Cheng-Mayer C. (2001). Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques. Journal of Virology. 75: 9287-9296.
43. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. (1999). Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology. 73: 4009-4018.
44. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS. (1996). Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Research and Human Retroviruses. 12: 1319-1328.
45. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. (2000). Protection of macaques against veginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine. 6: 207-210.
46. McCutchan FE. (2006). Global epidemiology of HIV. Journal of Medical Virology. 78(Suppl 1): S7-S12.
47. McKnight A, Clapham PR, Goudsmit J, Cheingsong-Popov R. Weber JN, Weiss RA. (1992). Development of HIV-1 group-specific neutralizing antibodies after seroconversion, AIDS. 6: 799-802.
48. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M. (2004). Neutralization profiles of newly transmitted human, immunodeficiency virus type 1 by manoclonal antibodies 2G12, 2F5, and 4E10. Journal of Virology. 78: 14039-14042.
49. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wolf H. (1987). Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. Journal of Virology. 61: 570-578.
50. Moore JP, Cao Y, Ho DD, Koup RA. (1994). Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. Journal of Virology. 68: 5142-5155.
51. Moore, JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. (1996). Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology. 70:427-444.
52. Moore JP, Parren PW, Burton DR. (2001). Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. Journal of Virology. 75: 5721-5729.
53. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao Y., Binley JK Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS. (2002). Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proceedings of the National Academy of Sciences of the United States of America. 99: 6913-6918.
54. Nyambi PN, Nkengasong J, Lewi P, Andries K, Janssens W, Fransen K, Heyndrickx L, Piot P, van der Groen G. (1996). Multivariate analysis of human immunodeficiency virus type 1 neutralization data. Journal of Virology. 70: 6235-6243.
55. Nyambi PN, Nkengasong J, Peeters M, Simon F, Eberle J, Janssens W, Fransen K, Willems B, Vereecken Y, Heyndrickx L. (1995). Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. Journal of Infectious Diseases. 172: 1228-1237.
56. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. (2007). Analysis,of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology. 346:441-453.
57. Pantophlet R, Burton DR. (2006). GP120: target for neutralizing HIV-1 antibodies, Annual Review of Immunology. 24: 739-769.
58. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of Virology. 75: 8340-8347.
59. Pellegrin I, Legrand E, Neau D, Bonot,P, Masquelier B, Pellegrin JL, Ragnaud JK Bernaird N, Fleury HJ. (1996). Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 11: 438-447.
60. Pinter, A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. (2004). The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. Journal of Virology. 78: 5205-5215.
61. Poignard P, Saphire EO, Parren PW, Burton DR. (2001). gp120: Biologic aspects of structural features. Annual Review of Immunology. 19: 253-274.
62. Porter KR, Mascola JR, Hupudio H, Ewing D, VanCott TC, Anthony RL, Corwin AL, Widodo S, Ertono S, McCutchan FE, Burke DS, Hayes CG, Wignall FS, Graham RR. (1997). Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 14: 1-6.
63. Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H. (2007). Susceptibility of Recently Transmitted Subtype B HIV-1 Variants to Broadly Neutralizing Antibodies. Journal of Virology. 81:8533-8542.
64. Richman DD, Wrin T, Little SJ, Petropoulos CJ. (2003). Rapid evolution of the neutralizing antibody response to HIV ripe 1 infection. Proceedings of the National Academy of Sciences of the United States of America. 100: 4144-4149.
65. Rizzuto C, Sodroski J. (2000). Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Research and Human Retroviruses. 16: 741-749.
66. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. (1998). A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280: 1949-1953.
67. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B. (2000). HIV-1 nomenclature proposal. Science. 288: 55-56.
68. Roux KH, Taylor KA. (2007). AIDS virus envelope spike structure. Current Opinion in Structural Biology. 17: 244-252.
69. Sagar M, Wu X, Lee S, Overbaugh J. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. Journal of Virology. 80: 9586-9598.
70. Salzwedel K, Smith ED, Dey B, Berger EA. (2000). Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. Journal of Virology. 74: 326-333.
71. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. (2002). The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Journal of Virology. 76: 7293-7305.
72. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. (2002). The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alphal - >2 mannose residues on the outer face of gp120. Journal of Virology. 76: 7306-7321.
73. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun-Vezinet F. (1998). Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nature Medicine. 4: 1032-1037.
74. Srivastava IK, Ulmer JB, Barnett SW. (2005). Role of neutralizing antibodies in protective immunity against HIV. Human Vaccines. 1: 45-60.
75. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. (2004). Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 12: 193-204.
76. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, Sodroski J. (1998). CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. Journal of Virology. 72: 4694-4703.
77. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard HF. (2005). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine. 11: 615-622.
78. UNAIDS. (2004). UNAIDS 2004 Report on the Global AIDS epidemic: 4th global report: UNAIDS.
79. UNAIDS GR. (2006). www.unaids.org.
80. Weber J, Fenyo EM, Beddows S, Kaleebu P, Bjorndal A. (1996). Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. Journal of Virology. 70: 7827-7832.
81. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. (2003). Antibody neutralization and escape by HIV-1. Nature. 422: 307-312.
82. Willey RL, Rutledge RA, Dias S, Folks T, Theodore T, Buckler CE, Martin MA. (1986). Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proceedings of the National Academy of Sciences of the United States of America. 83: 5038-5042.
83. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. (2006). Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. Journal of Virology. 80: 835-844.
84. Wyatt R, Sodroski J. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280: 1884-1888.
85. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. (2002). Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Research and Human Retroviruses. 18: 1207-1217.
86. Xu W, Hofmann-Lehmann R, McClure RM, Ruprecht RM. (2002). Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine. 20: 1956-1960.
87. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. (2006). Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathogens. 2: e83.
88. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. (2007). Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 445: 732-737.
89. Zhu P, Liu J, Bess J, Jr., Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. (2006). Distribution and three-dimensional structure ofAIDS virus envelope spikes. Nature. 441: 847-852.
90. Zolla-Pazner S. (2005). Improving on nature: focusing the immune response on the V3 loop. Human Antibodies. 14: 69-72.
91. Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK. (2004). The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Research and Human Retroviruses. 20: 1254-1258.
92. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR. (2005). Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. Journal of Virology. 79: 1252-1261.